Success Story: EB-2 NIW (National Interest Waiver) Approval for Pharmacist without a PhD

“EB-2 NIW (National Interest Waiver) Approval for Pharmacist without PhD” (Approval Notice)

Case Summary:

On 12/05/2012, we at Chen Immigration Law Associates received approval of an EB-2 NIW advanced degree professional for a client who is working as a Pharmacist but used to be pharmaceutical researcher. We presented our clients as an expert of the development of several new generic drug formulations, as well as the determination of proper drug administration and dosage for various commonly used drugs.

Before the client retained us, he was really worried that he might have a weak case, due to the fact that he only possessed a Master’s degree and had not completed any research for several years. Although the client did not have a particularly strong history of publication or citation, we were able to emphasize the significance of his contributions to the field of pharmaceutical research, as well as to the United States as a whole.

To strengthen his case, we drafted six strong recommendation letters in which we emphasized the significance of his past contributions to both the field of pharmaceutical research. Using our unique and highly successful strategies, we were able to present our client’s research accomplishments and future employment as a direct benefit to healthcare in the United States. Despite the fact that he was not currently employed in a research position, the USCIS recognized the merits of our client’s past research contributions and swiftly approved the petition without Request for Further Evidence (RFE).

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.